Results 91 to 100 of about 6,964 (243)

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 9, Page 1537-1566, September 2025.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Pharmacogenomics in the UK National Health Service: Progress towards implementation

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2241-2250, August 2025.
Over the past decade there has been considerable and growing enthusiasm about the promise of using genomics to inform healthcare. In particular, using genetic data to inform prescribing practice has emerged as a compelling policy priority for health systems around the world, not least in the NHS.
John H. McDermott, Maria Tsakiroglou, William G. Newman, Munir Pirmohamed   +3 more
wiley   +1 more source

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease

World Journal of Gastroenterology, 2010
To evaluate the relationship between thiopurine S-methyltransferase (TPMT) polymorphisms and thiopurine-induced adverse drug reactions (ADRs) in inflammatory bowel disease (IBD).Eligible articles that compared the frequency of TPMT polymorphisms among thiopurine-tolerant and -intolerant adult IBD patients were included.
Xian-Wen, Dong, Qing, Zheng, Ming-Ming, Zhu, Jing-Lu, Tong, Zhi-Hua, Ran   +4 more
openaire   +2 more sources

Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy

Turkish Journal of Hematology, 2014
Myelosuppression is a serious complication during treatment of acute lymphoblastic leukemia and the duration of myelosuppression is affected by underlying bone marrow failure syndromes and drug pharmacogenetics caused by genetic polymorphisms.
Burcu Fatma Belen, Turkız  Gursel, Nalan Akyurek, Meryem Albayrak, Zühre  Kaya, Ülker  Kocak   +5 more
doaj   +1 more source

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. [PDF]

, 2012
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increases the risk of
Abboudi, H, Macphee, IA
core   +2 more sources

Phenotyping and Genotyping Studies of Thiopurine S-Methyltransferase in Kazaks

Pharmaceutical Research, 2005
This study was conducted to investigate the thiopurine S-methyltransferase (TPMT) activity distribution and gene mutations in Kazaks, and compared the results with those of other ethnic groups.Erythrocyte TPMT activity was measured in Kazaks (n = 327) via a validated high-performance liquid chromatography assay.
Wei Hong, Shufeng Zhou, Chengrong Li, Jianping Zhang, Jueheng Wu, Min Huang   +5 more
openalex   +4 more sources

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 438-448, August 2025.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Current Status of Autoimmune Hepatitis in Japan [PDF]

, 2008
Autoimmune hepatitis (AIH) is a chronic and progressive disease characterized by histological interface hepatitis, hypergammaglobulinemia, and circulating autoantibodies. Multiple factors, including molecular mimicry, a genetic background including major
Miyake, Yasuhiro, Yamamoto, Kazuhide
core   +1 more source

Are single nucleotide polymorphisms underutilized for guiding treatment of inflammatory bowel disease?

Immunology &Cell Biology, Volume 103, Issue 6, Page 551-562, July 2025.
Patients with inflammatory bowel disease (IBD) show variation in their response to therapeutics. This review explores the contrast between heritable single nucleotide polymorphisms (SNPs) that contribute the pathogenesis of IBD, versus those that associate with response to treatments.
Jildou van der Werf, Nicholas Ian Fleming   +1 more
wiley   +1 more source

Managing the innovation supply chain to maximize personalized medicine. [PDF]

, 2014
Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient\u27s molecular characteristics and decipher his or her unique ...
Terzic, Andre, Waldman, Scott A
core   +2 more sources